Detalhe da pesquisa
1.
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 389(21): 1935-1948, 2023 Nov 23.
Artigo
Inglês
| MEDLINE | ID: mdl-37937763
2.
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain.
Mol Ther
; 32(2): 503-526, 2024 Feb 07.
Artigo
Inglês
| MEDLINE | ID: mdl-38155568
3.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
N Engl J Med
; 383(10): 931-943, 2020 09 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32469185
4.
Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens.
Cancer Immunol Immunother
; 72(10): 3149-3162, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37368077
5.
Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
Mol Cell Proteomics
; 20: 100136, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34391887
6.
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
BMC Cancer
; 22(1): 625, 2022 Jun 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35672677
7.
αß T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities.
Immunity
; 36(1): 79-91, 2012 Jan 27.
Artigo
Inglês
| MEDLINE | ID: mdl-22209676
8.
Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer.
Future Oncol
; 17(8): 965-977, 2021 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-33242257
9.
EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations.
Future Oncol
; 17(18): 2395-2408, 2021 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-33855865
10.
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.
Future Oncol
; 16(34): 2799-2808, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32854536
11.
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.
Cancer
; 125(6): 892-901, 2019 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30512189
12.
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer.
Future Oncol
; 15(20): 2371-2383, 2019 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-31354046
13.
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.
Future Oncol
; 15(25): 2905-2914, 2019 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-31370698
14.
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.
Future Oncol
; 14(27): 2861-2874, 2018 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-30336693
15.
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Mol Ther
; 25(10): 2245-2253, 2017 10 04.
Artigo
Inglês
| MEDLINE | ID: mdl-28803861
16.
Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
Lancet Oncol
; 18(6): 792-802, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28395880
17.
Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma.
Ann Surg Oncol
; 24(1): 135-141, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-27638681
18.
Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients.
Ann Surg Oncol
; 24(4): 947-951, 2017 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-28144760
19.
Landscape of Tumor Antigens in T Cell Immunotherapy.
J Immunol
; 195(11): 5117-22, 2015 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26589749
20.
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Lancet Oncol
; 16(7): 830-8, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-26051236